Baidu
map

Gut:丙型肝炎病毒预防性疫苗研究的重要进展

2017-12-05 佚名 中科院上海巴斯德所

近期,中国科学院上海巴斯德研究所在丙型肝炎病毒疫苗研究取得重要进展。相关成果“A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey”(丙型肝炎病毒三价亚单位疫苗在小鼠及恒河猴体内诱导广谱且协同性抗体反应)于11月27日在国际学术期刊Gu

近期,中国科学院上海巴斯德研究所在丙型肝炎病毒疫苗研究取得重要进展。相关成果“A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey”(丙型肝炎病毒三价亚单位疫苗在小鼠及恒河猴体内诱导广谱且协同性抗体反应)于11月27日在国际学术期刊Gut在线发表。

丙型肝炎病毒(HCV)是导致慢性肝炎,肝硬化及肝癌的主要病原体之一。目前全球大约有1亿8千万HCV感染病例,分布遍及全球大部分地区,并具有一定的基因型地区分布特征。目前新一代抗病毒药物可有效治愈HCV感染,但仍存在费用高昂,耐药性突变以及对于晚期患者发生肝硬化肝癌进程无法控制等不足,预防性疫苗对于丙肝疫情的控制仍然非常重要。HCV按照基因型划分主要分为7个基因型及众多亚型,由于基因高度变异导致其基因型及亚型的序列之间差别高达近30%左右,疫苗的研发难度很高。

研究人员在之前建立的1b基因型Con1株可溶性包膜蛋白E2(sE2)亚单位疫苗的基础上,根据全球基因型流行情况以及该单价苗诱导的中和抗体谱,制备了包含流行覆盖率和感染人数较多的1a基因型H77株、3a基因型S52株及1b基因型Con1株的sE2的三价亚单位疫苗。与三种单价疫苗相比,这种三价疫苗在小鼠体内诱导出更高效价的广谱性中和抗体。研究发现三价苗中不同单体sE2组分诱导的多种中和抗体对于Con1(1b基因型),JFH1(2a基因型),PR63cc(2a基因型)及S52(3a基因型)四株病毒具有较好的协同中和效应。研究还对三价苗在恒河猴中的免疫效果进行了研究,发现三价苗在非人灵长类动物中诱导的广谱中和抗体的效价和均一性均显着优于单价苗。此外三价苗在恒河猴体内诱导出HCV特异性T 细胞免疫反应。这些研究结果表明sE2三价亚单位疫苗具有产量高,单体组分间没有发现优势表位的竞争干扰,以及能诱导协同效应的广谱性中和抗体等优势,为未来多价苗的研发及疫苗产业化奠定了重要的基础。

该研究得到了科技部973项目、国家自然科学基金委重点项目和中科院“丙肝疫苗研发的免疫学研究创新团队” 国际合作伙伴计划的支持。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034784, encodeId=7d0a2034e8406, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Jun 19 13:34:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026382, encodeId=cf3720263824e, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 14 01:34:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274614, encodeId=82bb12e4614e2, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429545, encodeId=3daf1429545e9, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267374, encodeId=a05326e374c8, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 06 23:24:29 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034784, encodeId=7d0a2034e8406, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Jun 19 13:34:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026382, encodeId=cf3720263824e, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 14 01:34:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274614, encodeId=82bb12e4614e2, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429545, encodeId=3daf1429545e9, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267374, encodeId=a05326e374c8, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 06 23:24:29 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2034784, encodeId=7d0a2034e8406, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Jun 19 13:34:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026382, encodeId=cf3720263824e, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 14 01:34:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274614, encodeId=82bb12e4614e2, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429545, encodeId=3daf1429545e9, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267374, encodeId=a05326e374c8, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 06 23:24:29 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2034784, encodeId=7d0a2034e8406, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Jun 19 13:34:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026382, encodeId=cf3720263824e, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 14 01:34:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274614, encodeId=82bb12e4614e2, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429545, encodeId=3daf1429545e9, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267374, encodeId=a05326e374c8, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 06 23:24:29 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2034784, encodeId=7d0a2034e8406, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Jun 19 13:34:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026382, encodeId=cf3720263824e, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 14 01:34:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274614, encodeId=82bb12e4614e2, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429545, encodeId=3daf1429545e9, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Dec 07 05:34:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267374, encodeId=a05326e374c8, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 06 23:24:29 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-06 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

相关资讯

J Gastroenterol Hepatol:HCV患者接受DAA治疗后产生早期病毒学反应的重要性

在治疗开始后的1天,血清HCV RNA水平的降低与接受24周无干扰素治疗的患者的治疗结果无关;然而,在接受为期12周的治疗方案的患者其血清HCVRNA的减少是SVR的预测指标,因此有可能成为鉴别治疗失败的预测指标。

J Gastroenterol Hepatol:HBV与HCV联合感染阻断慢性丙型肝炎患者血小板计数恢复

PLT计数在HCV根除后恢复。HBV联合HCV感染阻断了PLT计数的恢复,尤其是在肝病晚期的CHC患者。

J Gastroenterol Hepatol:印度丙型肝炎病毒感染的临床概况

印度HCV感染在男性、中年人、来自低等社会经济地位的农村患者中更常见。常见的危险因素是牙科治疗和暴露于重复使用的注射器和针头。虽然最常见的表现是偶然发现,但仍有大量患者出现晚期肝病。

J Viral Hepat: HCV基因1、3型感染导致类似的脂肪变性

研究表明,HCV GT1和HCV GT3诱导的肝组织脂肪变性的主要差异是脂滴的大小,而不是脂滴的数量,不是脂滴的分布范围(HCV感染细胞,HCV未感染细胞)。

J Viral Hepat:低水平的硫酸脱氢表雄酮与HCV进展期肝纤维化相关

HCV患者,进展期肝纤维化与血清低水平的DHEA-S呈负相关。

J Viral Hepat:国际间比较:在DAA治疗之前,HCV患者HCC发生率较高和存活率较低

在整个环境下,HCC负担增加;HCC个体水平风险保持稳定或增加,HCC存活率仍然极低。

Baidu
map
Baidu
map
Baidu
map